Drug intelligence / Profile preview

aminoven

Development stage
Unknown
Lead developer
Fresenius Kabi
Modality
Small Molecules
Administration
Intravenous
01

Overview

Aminoven is a sterile, non-pyrogenic solution of amino acids designed for intravenous infusion as part of a parenteral nutrition regimen. Developed by Fresenius Kabi, it provides a comprehensive profile of essential, semi-essential, and non-essential amino acids, including taurine and tyrosine, to support metabolic requirements and protein synthesis in patients who cannot achieve adequate nutrition through oral or enteral routes. It is frequently utilized in clinical settings for patients with chronic conditions such as end-stage renal disease (ESRD) undergoing hemodialysis, as well as in post-operative or critically ill patients to prevent protein depletion and maintain nitrogen balance. The solution is available in various concentrations (5%, 10%, and 15%) and specialized formulations for pediatric use (Aminoven Infant).

Brand names
Aminoven
Other names
Aminoven 5%Aminoven 10%Aminoven 15%Aminoven Infantamino acid solution
02

Targets

Neuraminidase

Beyond the preview

Go deeper on aminoven.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminoven.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call